A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203

Hanmi Pharmaceutical

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: RLD2202

Drug: RLD2203

Study type

Interventional

Funder types

Industry

Identifiers

NCT05481307

HM-SARA-101

Details and patient eligibility

About

The purpose of this study is to evaluate pharmacokinetic/pharmacodynamic drug-drug interactions and safety/tolerability between RLD2202 and RLD2203 in healthy adult subjects

Enrollment

24 patients

Sex

All

Ages

19 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:
1. Healthy adults in the age between 19 and 50 years old
2. Body mass index (BMI) in the range of 18 to 27 kg/m2 and weight 50kg to 90kg.
3. After fully hearing and understanding the details of this clinical trial, Subjects who have willingness to sign of informed consent before the screening.
4. Subject who are eligible from physical examination, clinical laboratory test by investigators judgment.
Exclusion Criteria:
1. Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system
2. Subjects who judged ineligible by the investigator